Table 3 First-line Multikinase Inhibitor Treatment Patterns and Second-line Multikinase Inhibitor Treatment

	Sunitinib	Sorafenib
	(N = 85)	(N = 60)
Duration of treatment, months ¹
Median (95% CI)	6.6 (5.3, 11.1)	5.8 (4.1, 8.1)
Mean (SE)	9.9 (0.9)	8.3 (0.9)
Patients who discontinued first-line treatment, N (%)	66 (77.6)	51 (85.0)
Reasons for discontinuation, N (%) ²
Adverse events	10 (11.8)	3 (5.0)
Progressive disease	53 (62.4)	35 (58.3)
Other	9 (10.6)	14 (23.3)
Patients with first-line treatment interruption, N (%)	29 (34.1)	16 (26.7)
Reasons for interruptions, N (%) ³
Adverse Events	20 (23.5)	14 (23.3)
Other	15 (17.6)	3 (5.0)
Patients with first-line dose reduction, N (%)	30 (35.3)	23 (38.3)
Reasons for dose reduction, N (%) ⁴
Adverse Events	26 (30.6)	22 (36.7)
General clinical conditions worsening	5 (5.9)	1 (1.7)
Patients who received second-line angiogenesis inhibitor, N (%)	15 (17.6)	23 (38.3)
Sunitinib, N (%)	--	21 (35.0)
Sorafenib, N (%)	15 (17.6)	--
Temsirolimus, N (%)	0 (0.0)	2 (3.3)

Notes:
1. 11 patients who received sunitinib and 6 patients who received sorafenib and who had not ended first-line treatment by the time of data collection were treated as censored observations as of the date of last follow-up.
2. Patients may have more than one reason for discontinuation of first-line treatment.
3. For patients with more than one treatment interruption during the first-line treatment, the reasons for each treatment interruption are included.
4. For patients with more than one dose reduction during the first-line treatment, the reasons for each dose reduction are included.

ISSN: 1471-2407